Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients

Luo,Yanwei; Wang,Xinye; Niu,Weihong; Wang,Heran; Wen,Qiuyuan; Fan,Songqing; Zhao,Ran; Li,Zheng; Xiong,Wei; Peng,Shuping; Zeng,Zhaoyang; Li,Xiaoling; Li,Guiyuan; Tan,Ming; Zhou,Ming

doi:10.3892/ol.2016.5482

Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients

Authors:
- Yanwei Luo
- Xinye Wang
- Weihong Niu
- Heran Wang
- Qiuyuan Wen
- Songqing Fan
- Ran Zhao
- Zheng Li
- Wei Xiong
- Shuping Peng
- Zhaoyang Zeng
- Xiaoling Li
- Guiyuan Li
- Ming Tan
- Ming Zhou
View Affiliations

Affiliations: Cancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China, Department of Pathology, The Second Xiang‑Ya Hospital, Central South University, Changsha, Hunan 410011, P.R. China, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA
Published online on: December 12, 2016 https://doi.org/10.3892/ol.2016.5482
Pages: 867-874

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer, the second most common cancer worldwide, is the leading cause of cancer-associated mortality in women, accounting for ~15% of all cancer-associated mortalities in women. The development, local invasion and metastasis of breast cancer are associated with the dysregulation and mutation of numerous genes and epigenetic mechanisms, including coding RNA and non‑coding RNA, such as microRNAs (miRs/miRNAs). Previous studies have shown a dual‑faced role of miR‑125b in breast cancer. In the present study, a total of 221 paraffin‑embedded breast cancer and 49 paraffin‑embedded non‑cancerous breast tissue samples were collected. In situ hybridization was used to analyze the expression of miR‑125b in the breast cancer tissues. Spearman's rank correlation analysis was used to analyze the expression correlation between miR‑125b and human epidermal growth factor 2 (HER2). The overall survival estimates over time were calculated using the Kaplan‑Meier method with log‑rank test. It was found that miR‑125b expression was significantly increased in the breast cancer tissues compared with that in the non‑cancerous tissues, and high miR‑125b expression indicated a poor prognosis in the breast cancer patients. In addition, miR‑125b expression was positively correlated with HER2, but not with progesterone receptor and estrogen receptor. Notably, high miR‑125b expression was significantly correlated with tumor size and Tumor‑Node‑Metastasis stage in the HER2‑positive breast cancer patients, along with a poor prognosis. The present study provides clinical data to confirm the oncogenic potential of miR‑125b, particularly in HER2‑positive human breast cancer. Thus, identification of miR‑125b may be a potential molecular biomarker for the prediction of clinical outcomes in breast cancer patients, particularly HER2‑positive cases that will receive paclitaxel-based neoadjuvant chemotherapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, LortetTieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Eroles P, Bosch A, Pérez-Fidalgo JA and Lluch A: Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev. 38:698–707. 2012. View Article : Google Scholar : PubMed/NCBI
3	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ: Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
4	Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 34:1071–1077. 2014.PubMed/NCBI
5	Kontorovich T, Levy A, Korostishevsky M, Nir U and Friedman E: Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int J Cancer. 127:589–597. 2010. View Article : Google Scholar : PubMed/NCBI
6	Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM and Rosenberg A: MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 219:214–221. 2009. View Article : Google Scholar : PubMed/NCBI
7	Matamala N, Vargas MT, GonzalezCampora R, Minambres R, Arias JI, Menendez P, AndresLeon E, GomezLopez G, Yanowsky K, CalveteCandenas J, et al: Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 61:1098–1106. 2015. View Article : Google Scholar : PubMed/NCBI
8	Banzhaf-Strathmann J and Edbauer D: Good guy or bad guy: The opposing roles of microRNA 125b in cancer. Cell Commun Signal. 12:302014. View Article : Google Scholar : PubMed/NCBI
9	Ferracin M, Bassi C, Pedriali M, Pagotto S, D'Abundo L, Zagatti B, Corrà F, Musa G, Callegari E, Lupini L, et al: miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer. 12:1302013. View Article : Google Scholar : PubMed/NCBI
10	Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, et al: miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 71:3552–3562. 2011. View Article : Google Scholar : PubMed/NCBI
11	Feliciano A, Castellvi J, ArteroCastro A, Leal JA, Romagosa C, HernandezLosa J, Peg V, Fabra A, Vidal F, Kondoh H, et al: miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. PLoS One. 8:e762472013. View Article : Google Scholar : PubMed/NCBI
12	Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS and Benz CC: Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 282:1479–1486. 2007. View Article : Google Scholar : PubMed/NCBI
13	Tang F, Zhang R, He Y, Zou M, Guo L and Xi T: MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One. 7:e354352012. View Article : Google Scholar : PubMed/NCBI
14	Wang HJ, Guo YQ, Tan G, Dong L, Cheng L, Li KJ, Wang ZY and Luo HF: miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem. 114:2248–2257. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, et al: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 285:21496–21507. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z and Luo H: Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 7:e342102012. View Article : Google Scholar : PubMed/NCBI
17	Fan SQ, Ma J, Zhou J, Xiong W, Xiao BY, Zhang WL, Tan C, Li XL, Shen SR, Zhou M, et al: Differential expression of Epstein-Barr virus-encoded RNA and several tumor-related genes in various types of nasopharyngeal epithelial lesions and nasopharyngeal carcinoma using tissue microarray analysis. Hum Pathol. 37:593–605. 2006. View Article : Google Scholar : PubMed/NCBI
18	Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
19	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
20	Nakanishi H, Taccioli C, Palatini J, FernandezCymering C, Cui R, Kim T, Volinia S and Croce CM: Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene. 33:702–712. 2014. View Article : Google Scholar : PubMed/NCBI
21	Henson BJ, Bhattacharjee S, O'Dee DM, Feingold E and Gollin SM: Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer. 48:569–582. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu LH, Li H, Li JP, Zhong H, Zhang HC, Chen J and Xiao T: miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun. 416:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
23	Smits M, Wurdinger T, van het Hof B, Drexhage JA, Geerts D, Wesseling P, Noske DP, Vandertop WP, de Vries HE and Reijerkerk A: Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. FASEB J. 26:2639–2647. 2012. View Article : Google Scholar : PubMed/NCBI
24	He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R, Li Q, Wang XR, Peiper SS, Lu Z, et al: Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. EMBO Rep. 13:1116–1122. 2012. View Article : Google Scholar : PubMed/NCBI
25	Bousquet M, Harris MH, Zhou B and Lodish HF: MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA. 107:21558–21563. 2010. View Article : Google Scholar : PubMed/NCBI
26	Willimott S and Wagner SD: miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem. 287:2608–2617. 2012. View Article : Google Scholar : PubMed/NCBI
27	Xia HF, He TZ, Liu CM, Cui Y, Song PP, Jin XH and Ma X: MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem. 23:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
28	Le MT, Teh C, ShyhChang N, Xie H, Zhou B, Korzh V, Lodish HF and Lim B: MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 23:862–876. 2009. View Article : Google Scholar : PubMed/NCBI
29	Bousquet M, Quelen C, Rosati R, MansatDe MV, La Starza R, Bastard C, Lippert E, Talmant P, Lafage-Pochitaloff M, Leroux D, et al: Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 205:2499–2506. 2008. View Article : Google Scholar : PubMed/NCBI
30	Chapiro E, Russell LJ, Struski S, Cavé H, Radford-Weiss I, Valle VD, Lachenaud J, Brousset P, Bernard OA, Harrison CJ and Nguyen-Khac F: A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia. 24:1362–1364. 2010. View Article : Google Scholar : PubMed/NCBI
31	Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V, Castoro C, Mastracci L, Farinati F, Nitti D, et al: The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol. 44:1804–1810. 2013. View Article : Google Scholar : PubMed/NCBI
32	He J, Jing Y, Li W, Qian X, Xu Q, Li FS, Liu LZ, Jiang BH and Jiang Y: Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS One. 8:e566472013. View Article : Google Scholar : PubMed/NCBI
33	Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, Kitamura Y, Shimoyama T, Maeda Y, Takahashi F, et al: Chemotherapy-regulated microRNA-125-HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small cell lung cancer. Mol Cancer Ther. 14:1414–1423. 2015. View Article : Google Scholar : PubMed/NCBI
34	Shang C, Lu YM and Meng LR: MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2. Med Sci Monit. 18:BR149–BR155. 2012. View Article : Google Scholar : PubMed/NCBI
35	Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ and White RW deVere: An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA. 104:19983–19988. 2007. View Article : Google Scholar : PubMed/NCBI
36	Schwarzenbacher D, Balic M and Pichler M: The role of microRNAs in breast cancer stem cells. Int J Mol Sci. 14:14712–14723. 2013. View Article : Google Scholar : PubMed/NCBI
37	Le MT, ShyhChang N, Khaw SL, Chin L, Teh C, Tay J, O'Day E, Korzh V, Yang H, Lal A, et al: Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet. 7:e10022422011. View Article : Google Scholar : PubMed/NCBI
38	Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res. 17:132015. View Article : Google Scholar : PubMed/NCBI
39	Zheng Y, Li S, Boohaker RJ, Liu X, Zhu Y, Zhai L, Li H, Gu F, Fan Y, Lang R, et al: A microRNA expression signature in taxane-anthracycline-based neoadjuvant chemotherapy response. J Cancer. 6:671–677. 2015. View Article : Google Scholar : PubMed/NCBI